Journal article · 2013 · Open access

ALS disease modeling and drug screening using patient-specific iPS cells

Naohiro Egawa, Haruhisa Inoue

Rinsho Shinkeigaku, 53(11), 1020–1022 · Published 1 January 2013 · DOI 10.5692/clinicalneurol.53.1020

Open PDFView at the publisherCite this paper

In brief

“ALS disease modeling and drug screening using patient-specific iPS cells” is a 2013 journal article by Naohiro Egawa and Haruhisa Inoue, published in Rinsho Shinkeigaku. OpenAlex counts 6 citations as of 18 November 2026. It is open access: the full text is free to read at Rinsho Shinkeigaku.

Citations
6
Most cited in
2015 (2)
Field-weighted impact
0.54
References
7
Authors
2

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder in which motor neuron (MN) loss in the spinal cord leads to progressive paralysis and death. Cytosolic aggregations in ALS MNs are composed of Tar DNA-binding protein-43 (TDP-43). Genetic analysis has identified more than twenty mutations of TDP-43 in ALS cases. Although accumulating evidence provides several hypotheses of disease mechanism, it is still needed to discover effective cure for ALS. We aimed to reveal cellular phenotypes in ALS MNs for identifying a drug-screening target for ALS using patient-specific induced pluripotent stem cells (iPSCs). To generate patient-specific iPSCs, dermal fibroblasts were obtained by biopsy from ALS patients carrying mutant TDP-43. The fibroblasts were reprogrammed by retrovirus or episomal vectors. Disease-specific iPSCs were differentiated into MNs expressing HB9 and SMI-32. Despite short culture period, ALS MNs recapitulated several disease phenotypes including detergent-insoluble TDP-43, shortened neurites and cellular vulnerability that observed in patient and animal models. Anacardic acid treatment reverted those phenotypes. Disease-specific iPSCs might provide a first step for drug-screening platform for ALS using patient-specific iPSCs.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Egawa, N., & Inoue, H. (2013). ALS disease modeling and drug screening using patient-specific iPS cells. Rinsho Shinkeigaku, 53(11), 1020–1022. https://doi.org/10.5692/clinicalneurol.53.1020

MLA 9

Egawa, Naohiro, and Haruhisa Inoue. “ALS disease modeling and drug screening using patient-specific iPS cells.” Rinsho Shinkeigaku, vol. 53, no. 11, 2013, pp. 1020–1022. https://doi.org/10.5692/clinicalneurol.53.1020.

Chicago

Egawa, Naohiro and Haruhisa Inoue. 2013. “ALS disease modeling and drug screening using patient-specific iPS cells.” Rinsho Shinkeigaku 53 (11): 1020–1022. https://doi.org/10.5692/clinicalneurol.53.1020.

Harvard

Egawa, N. and Inoue, H. (2013) ‘ALS disease modeling and drug screening using patient-specific iPS cells’, Rinsho Shinkeigaku, 53(11), pp. 1020–1022. doi:10.5692/clinicalneurol.53.1020.

IEEE

N. Egawa and H. Inoue, “ALS disease modeling and drug screening using patient-specific iPS cells,” Rinsho Shinkeigaku, vol. 53, no. 11, pp. 1020–1022, 2013, doi: 10.5692/clinicalneurol.53.1020.

BibTeX

@article{egawa2013disease,
  title     = {{ALS disease modeling and drug screening using patient-specific iPS cells}},
  author    = {Egawa, Naohiro and Inoue, Haruhisa},
  journal   = {Rinsho Shinkeigaku},
  year      = {2013},
  volume    = {53},
  number    = {11},
  pages     = {1020--1022},
  doi       = {10.5692/clinicalneurol.53.1020},
  url       = {https://doi.org/10.5692/clinicalneurol.53.1020}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201411
201522
201911
202111
202611

Its field-weighted citation impact is 0.54: it has been cited 0.54 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research

  • amyotrophic lateral sclerosis
  • TDP-43 mutations
  • induced pluripotent stem cells
  • motor neurons
  • disease modeling
  • drug screening
  • anacardic acid
  • TDP-43 aggregation

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Egawa, N., & Inoue, H. (2013). ALS disease modeling and drug screening using patient-specific iPS cells. Rinsho Shinkeigaku, 53(11), 1020–1022. https://doi.org/10.5692/clinicalneurol.53.1020

How many times has this paper been cited?

6 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Rinsho Shinkeigaku: sign in and open the PDF from this page.

Who wrote this paper?

Naohiro Egawa, Haruhisa Inoue.

What is the DOI of this paper?

10.5692/clinicalneurol.53.1020, permanently at https://doi.org/10.5692/clinicalneurol.53.1020. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.